Abbreviated Name

PCA3 Ref Set App-T2 ERG-Sanda (2014)

Lead Investigator

Sanda, Martin — Emory University

Coordinating Investigator

Feng, Ziding — Fred Hutchinson Cancer Center

Involved Investigators

• Groskopf, Jack — Hologic Gen-Probe Incorporated
• Feng, Ziding — Fred Hutchinson Cancer Center
• Chan, Daniel — Johns Hopkins Medical Institutions
• Sanda, Martin — Emory University

Abstact

Aims

Primary Specific Aims Aim 1:   To validate the performance of urinary T2:erg in a multiplex model in combination with PCA3 predicting the diagnosis of histologically clinically significant prostate cancer among men without prior evidence of prostate cancer Secondary Aims Aim 1:   To evaluate the sensitivity, specificity, PPV, NPV and absolute risk prediction by T2:erg/PCA3 combined and multiplexed with other biomarkers and clinical variables in the detection of histologically clinically significant prostate cancer Aim 2:    To validate the performance of urinary T2:erg in a multiplex model in combination with PCA3 predicting the diagnosis of ANY prostate cancer Aim 3:    To investigate whether the multiplex model performance is improved by addition of % free PSA, PSAV, -2proPSA, and other markers in development Aim 4:   To evaluate the correlation between urinary and tissue based T2:erg and prostate biopsy tumor grade

Analytic Method

Transcription mediated amplification based assay

Biomarkers

• PCA3
• TMPRSS2:ERG

Data Collections

• No data available at this time for this protocol

Protocol ID

376

Protocol Type

Reference Set

Field of Research

Genomics

Collaborative Group

Prostate and Urologic Cancers Research Group

Cancer Types

• Malignant neoplasm of prostate

Phased Status

2